Dusseldorf - Delayed Quote • EUR
CStone Pharmaceuticals (PH4.DU)
At close: April 26 at 7:30 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
463,842.0000
463,842.0000
481,363.0000
243,718.0000
1,038,832.0000
Cost of Revenue
159,547.0000
159,547.0000
202,985.0000
106,832.0000
241,421.0000
Gross Profit
304,295.0000
304,295.0000
278,378.0000
136,886.0000
797,411.0000
Operating Expense
884,140.0000
884,140.0000
1,181,475.0000
1,930,359.0000
1,861,832.0000
Operating Income
-579,845.0000
-579,845.0000
-903,097.0000
-1,793,473.0000
-1,064,421.0000
Net Non Operating Interest Income Expense
13,067.0000
13,067.0000
1,195.0000
7,561.0000
22,841.0000
Pretax Income
-367,234.0000
-367,234.0000
-902,678.0000
-1,920,100.0000
-1,220,999.0000
Net Income Common Stockholders
-367,234.0000
-367,234.0000
-902,678.0000
-1,920,100.0000
-1,220,999.0000
Diluted NI Available to Com Stockholders
-367,234.0000
-367,234.0000
-902,678.0000
-1,920,100.0000
-1,220,999.0000
Basic EPS
-0.29
--
-0.77
-1.65
-1.17
Diluted EPS
-0.29
--
-0.77
-1.65
-1.17
Basic Average Shares
1,263,073.0000
--
1,172,839.0000
1,165,209.0000
1,046,032.0000
Diluted Average Shares
1,263,073.0000
--
1,172,839.0000
1,165,209.0000
1,046,032.0000
Rent Expense Supplemental
3,513.0000
3,513.0000
3,069.0000
2,475.0000
3,160.0000
Total Expenses
1,043,687.0000
1,043,687.0000
1,384,460.0000
2,037,191.0000
2,103,253.0000
Net Income from Continuing & Discontinued Operation
-367,234.0000
-367,234.0000
-902,678.0000
-1,920,100.0000
-1,220,999.0000
Normalized Income
-546,426.0000
-546,426.0000
-840,749.0000
-1,854,995.0000
-1,223,416.0000
Interest Income
24,886.0000
24,886.0000
9,672.0000
9,803.0000
24,161.0000
Interest Expense
11,819.0000
11,819.0000
8,477.0000
2,242.0000
1,320.0000
Net Interest Income
13,067.0000
13,067.0000
1,195.0000
7,561.0000
22,841.0000
EBIT
-355,415.0000
-355,415.0000
-894,201.0000
-1,917,858.0000
-1,219,679.0000
EBITDA
-297,225.0000
-297,225.0000
-849,661.0000
-1,895,197.0000
-1,204,878.0000
Reconciled Cost of Revenue
159,547.0000
159,547.0000
202,985.0000
106,832.0000
241,421.0000
Reconciled Depreciation
58,190.0000
58,190.0000
44,540.0000
22,661.0000
14,801.0000
Net Income from Continuing Operation Net Minority Interest
-367,234.0000
-367,234.0000
-902,678.0000
-1,920,100.0000
-1,220,999.0000
Total Unusual Items Excluding Goodwill
179,192.0000
179,192.0000
-61,929.0000
-65,105.0000
2,417.0000
Total Unusual Items
179,192.0000
179,192.0000
-61,929.0000
-65,105.0000
2,417.0000
Normalized EBITDA
-476,417.0000
-476,417.0000
-787,732.0000
-1,830,092.0000
-1,207,295.0000
12/31/2020 - 6/25/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade